Global Radiotherapy, Nuclear Medicine & Radiopharmaceuticals Market 2022-2028

May 2022 | 71 pages | ID: GE815C3FC63AEN
Gen Consulting Company

Abstracts

Radiation therapy is the treatment of cancer and other diseases with radiation. Radiation in various forms is used to kill the cancer cells by preventing them from multiplying. Therapeutic radiology may be used to cure or control cancer, or to alleviate some of the symptoms associated with cancer. Gen Consulting Company predicts that the global radiotherapy, nuclear medicine & radiopharmaceuticals market is estimated to touch a valuation of USD 30,329 million, registering a CAGR of 9.4% during the forecast period (2022-2028).

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global radiotherapy, nuclear medicine & radiopharmaceuticals market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the radiotherapy, nuclear medicine & radiopharmaceuticals industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, application, and region. The global market for radiotherapy, nuclear medicine & radiopharmaceuticals can be segmented by product: radiopharmaceuticals, radiotherapy. According to the research, the radiopharmaceuticals segment had the largest share in the global radiotherapy, nuclear medicine & radiopharmaceuticals market. Radiotherapy, nuclear medicine & radiopharmaceuticals market is further segmented by application: bone metastasis, endocrine tumor, hyperthyroidism, lymphoma, oncology, others. Based on region, the radiotherapy, nuclear medicine & radiopharmaceuticals market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW).

By product:

• radiopharmaceuticals
• radiotherapy

By application:

• bone metastasis
• endocrine tumor
• hyperthyroidism
• lymphoma
• oncology
• others

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The radiopharmaceuticals market is further segmented into diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals. Gen Consulting Company research indicates that the diagnostic radiopharmaceuticals segment occupied the largest share of this market in 2021 and is expected to draw the highest demand in coming years. Furthermore, the radiopharmaceuticals by production method market has been categorized into cyclotron, generator, nuclear reactor. The radiotherapy market is further divided into external beam radiation therapy, internal radiation therapy or brachytherapy, systemic radiotherapy.

The report explores the recent developments and profiles of key vendors in the Global Radiotherapy, Nuclear Medicine & Radiopharmaceuticals Market, including Accuray Inc., Advanced Accelerator Applications (Novartis International AG), Australian Nuclear Science and Technology Organisation (ANSTO), Bracco S.p.A., Cardinal Health, Inc., Curium SAS, Eckert & Ziegler Strahlen%li%und Medizintechnik AG, ECZACIBASI-MONROL Nuclear Products Co., Elekta AB, GE Healthcare, IBA Molecular (IBAM), IRE - IRE ELiT, Jubilant Life Sciences Ltd., Lantheus Holdings, Inc., Nordion Inc, NTP Radioisotopes SOC Ltd., Varian Medical Systems Inc., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global radiotherapy, nuclear medicine & radiopharmaceuticals market.
• To classify and forecast the global radiotherapy, nuclear medicine & radiopharmaceuticals market based on product, application, region.
• To identify drivers and challenges for the global radiotherapy, nuclear medicine & radiopharmaceuticals market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global radiotherapy, nuclear medicine & radiopharmaceuticals market.
• To identify and analyze the profile of leading players operating in the global radiotherapy, nuclear medicine & radiopharmaceuticals market.

Why Choose This Report

• Gain a reliable outlook of the global radiotherapy, nuclear medicine & radiopharmaceuticals market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY PRODUCT

Radiopharmaceuticals
Radiotherapy

PART 6. MARKET BREAKDOWN BY APPLICATION

Bone metastasis
Endocrine tumor
Hyperthyroidism
Lymphoma
Oncology
Others

PART 7. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 8. KEY COMPANIES

Accuray Inc.
Advanced Accelerator Applications (Novartis International AG)
Australian Nuclear Science and Technology Organisation (ANSTO)
Bracco S.p.A.
Cardinal Health, Inc.
Curium SAS
Eckert & Ziegler Strahlen- und Medizintechnik AG
ECZACIBASI-MONROL Nuclear Products Co.
Elekta AB
GE Healthcare
IBA Molecular (IBAM)
IRE - IRE ELiT
Jubilant Life Sciences Ltd.
Lantheus Holdings, Inc.
Nordion Inc
NTP Radioisotopes SOC Ltd.
Varian Medical Systems Inc.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER